LIVIVO - Search results -

Search results

Result 1 - 10 of total 32

Search options

Article: Comparison and Analysis of Diffusion Models: Growth Kinetics of Diiron Boride Layers on ASTM A283 Steel.

Ortiz-Domínguez, Martín / Gómez-Vargas, Oscar Armando / Bárcenas-Castañeda, Mariana / Castellanos-Escamilla, Víctor Augusto

Materials (Basel, Switzerland)

2022 Volume 15, Issue 23

Abstract: Hard-coated surfacing of a few micrometers is widely applied to increase the efficiency of tools, e.g., for cutting, forming, and casting applications. Therefore, the base thermodiffusion surface treatment is a practical solution to these issues by ... ...

Abstract	Hard-coated surfacing of a few micrometers is widely applied to increase the efficiency of tools, e.g., for cutting, forming, and casting applications. Therefore, the base thermodiffusion surface treatment is a practical solution to these issues by hardening surface layers with interstitial elements such as carbon, nitrogen, and boron. In particular, within this study, the growth kinetics of an iron boride layer on ASTM 283 steel were investigated with two diffusion models of the powder-pack boriding technique in the temperature range of 1123-1273 K with different treatment periods. The first model, called the steady-state diffusion model, used the modified version of the mass balance equations at the Fe
Language	English
Publishing date	2022-11-26
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2487261-1
ISSN	1996-1944
ISSN	1996-1944
DOI	10.3390/ma15238420
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Asociación entre funcionalidad familiar y deterioro cognitivo leve en la familia con adulto mayor.

Jiménez Lara, María Fernanda / Villarreal Ríos, Enrique / Galicia Rodríguez, Liliana / Franco Saldaña, Mireya / Ruiz Bárcenas, María Yaquelín / Guerreo Mancera, Mariana Del Rayo

Revista espanola de geriatria y gerontologia

2023 Volume 59, Issue 2, Page(s) 101452

Abstract: Aim: To determine the association between family functionality and mild cognitive impairment in the family with the elderly.: Methodology: Analytical cross-sectional design in families with geriatric patients. A family with a geriatric patient was ... ...

Title translation	Association between family functionality and mild cognitive impairment in the family with the elderly.
Abstract	Aim: To determine the association between family functionality and mild cognitive impairment in the family with the elderly. Methodology: Analytical cross-sectional design in families with geriatric patients. A family with a geriatric patient was considered when at least one of its members was over 60years of age. The comparison groups were the family with a geriatric patient without cognitive impairment and the family with a geriatric patient with mild cognitive impairment determined with the MoCA instrument. Family functionality was evaluated with the family APGAR instrument, which identifies three categories: family functionality, moderate family dysfunction, and severe family dysfunction. Statistical analysis included Chi square and Mann-Whitney test. Results: In the family with a geriatric patient, in the group without cognitive impairment the prevalence of family functionality is 89.7% and in the group with mild cognitive impairment the prevalence of family functionality is 59.3% (MW=4.87, P<.000). Conclusion: There is an association between family functionality and mild cognitive impairment.
MeSH term(s)	Aged ; Humans ; Cross-Sectional Studies ; Cognitive Dysfunction/epidemiology ; Research Design
Language	Spanish
Publishing date	2023-12-11
Publishing country	Spain
Document type	English Abstract ; Journal Article
ZDB-ID	605609-x
ISSN	1578-1747 ; 0211-139X
ISSN (online)	1578-1747
ISSN	0211-139X
DOI	10.1016/j.regg.2023.101452
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2677: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Thermodynamic properties of triangle-well fluids in two dimensions: MC and MD simulations.

Reyes, Yuri / Bárcenas, Mariana / Odriozola, Gerardo / Orea, Pedro

The Journal of chemical physics

2016 Volume 145, Issue 17, Page(s) 174505

Abstract: With the aim of providing complementary data of the thermodynamics properties of the triangular well potential, the vapor/liquid phase diagrams for such potential with different interaction ranges were calculated in two dimensions by Monte Carlo and ... ...

Abstract	With the aim of providing complementary data of the thermodynamics properties of the triangular well potential, the vapor/liquid phase diagrams for such potential with different interaction ranges were calculated in two dimensions by Monte Carlo and molecular dynamics simulations; also, the vapor/liquid interfacial tension was calculated. As reported for other interaction potentials, it was observed that the reduction of the dimensionality makes the phase diagram to shrink. Finally, with the aid of reported data for the same potential in three dimensions, it was observed that this potential does not follow the principle of corresponding states.
Language	English
Publishing date	2016-11-07
Publishing country	United States
Document type	Journal Article
ZDB-ID	3113-6
ISSN	1089-7690 ; 0021-9606
ISSN (online)	1089-7690
ISSN	0021-9606
DOI	10.1063/1.4967254
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Bonn / Germany

Z 4' 49/16: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group.

González-López, Tomás José / Bárez, Abelardo / Bernardo-Gutiérrez, Angel / Bernat, Silvia / Canaro-Hirnyk, Mariana / Entrena-Ureña, Laura / Fernández-Fuertes, Fernando / Guinea de Castro, José María / Jiménez-Bárcenas, Reyes / Pascual-Izquierdo, Cristina / Sánchez-González, Blanca / Jarque, Isidro

Infectious diseases and therapy

2022 Volume 12, Issue 2, Page(s) 303–315

Abstract: Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease with highly variable presentation, characteristics, and clinical course. Thrombocytopenia is a common complication of many viral infections, including SARS-CoV-2. In addition, both ... ...

Abstract	Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease with highly variable presentation, characteristics, and clinical course. Thrombocytopenia is a common complication of many viral infections, including SARS-CoV-2. In addition, both de novo ITP and exacerbation of ITP after vaccination against SARS-CoV-2 have been reported. Patients infected with SARS-CoV-2 develop a prothrombotic coagulopathy called COVID-19-associated coagulopathy (CAC). In addition, autoimmune hematological disorders secondary to SARS-CoV-2 infection, mainly ITP and autoimmune hemolytic anemia (AIHA), have been described. Furthermore, SARS-CoV-2 infection has been associated with exacerbation of autoimmune processes, including ITP. In fact, there is evidence of a high relapse rate in patients with preexisting ITP and COVID-19. As for vaccination against SARS-CoV-2, hematological adverse events (HAE) are practically anecdotal. The most common HAE is thrombocytopenia-associated thrombosis syndrome (TTS) linked to vectored virus vaccines. Other HAEs are very rare, but should be considered in patients with previous complement activation disease or autoimmunity. In patients with ITP who are vaccinated against SARS-CoV-2, the main complication is exacerbation of ITP and the bleeding that may result. In fact, this complication occurs in 12% of patients, with splenectomized and refractory patients with more than five lines of previous treatment and platelet counts below 50 × 10
Language	English
Publishing date	2022-12-15
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2701611-0
ISSN	2193-6382 ; 2193-8229
ISSN (online)	2193-6382
ISSN	2193-8229
DOI	10.1007/s40121-022-00745-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: COVID-19 Vaccines and Autoimmune Hematologic Disorders.

Mingot-Castellano, María Eva / Butta, Nora / Canaro, Mariana / Gómez Del Castillo Solano, María Del Carmen / Sánchez-González, Blanca / Jiménez-Bárcenas, Reyes / Pascual-Izquierdo, Cristina / Caballero-Navarro, Gonzalo / Entrena Ureña, Laura / José González-López, Tomás / On Behalf Of The Gepti

Vaccines

2022 Volume 10, Issue 6

Abstract: Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally ... ...

Abstract	Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, although the incidence of these AEs is extremely low, their evolution may lead to life-threatening scenarios if treatment is not readily initiated. Hematologic autoimmune AEs have been associated with both mRNA and adenoviral vector-based SARS-CoV-2 vaccines. The main reported entities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans syndrome, and a newly described disorder, so-called vaccine-induced immune thrombotic thrombocytopenia (VITT). The hallmark of VITT is the presence of anti-platelet factor 4 autoantibodies able to trigger platelet activation. Patients with VITT present with thrombocytopenia and may develop thrombosis in unusual locations such as cerebral beds. The management of hematologic autoimmune AEs does not differ significantly from that of these disorders in a non-vaccine context, thus addressing autoantibody production and bleeding/thromboembolic risk. This means that clinicians must be aware of their distinctive signs in order to diagnose them and initiate treatment as soon as possible.
Language	English
Publishing date	2022-06-16
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines10060961
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Novel Therapies to Address Unmet Needs in ITP.

Mingot-Castellano, María Eva / Bastida, José María / Caballero-Navarro, Gonzalo / Entrena Ureña, Laura / González-López, Tomás José / González-Porras, José Ramón / Butta, Nora / Canaro, Mariana / Jiménez-Bárcenas, Reyes / Gómez Del Castillo Solano, María Del Carmen / Sánchez-González, Blanca / Pascual-Izquierdo, Cristina / On Behalf Of The Gepti

Pharmaceuticals (Basel, Switzerland)

2022 Volume 15, Issue 7

Abstract: Primary immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet counts and subsequent bleeding risk. Although current corticosteroid-based ITP therapies are able to improve platelet counts, up to 70% of subjects with an ITP ... ...

Abstract	Primary immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet counts and subsequent bleeding risk. Although current corticosteroid-based ITP therapies are able to improve platelet counts, up to 70% of subjects with an ITP diagnosis do not achieve a sustained clinical response in the absence of treatment, thus requiring a second-line therapy option as well as additional care to prevent bleeding. Less than 40% of patients treated with thrombopoietin analogs, 60% of those treated with splenectomy, and 20% or fewer of those treated with rituximab or fostamatinib reach sustained remission in the absence of treatment. Therefore, optimizing therapeutic options for ITP management is mandatory. The pathophysiology of ITP is complex and involves several mechanisms that are apparently unrelated. These include the clearance of autoantibody-coated platelets by splenic macrophages or by the complement system, hepatic desialylated platelet destruction, and the inhibition of platelet production from megakaryocytes. The number of pathways involved may challenge treatment, but, at the same time, offer the possibility of unveiling a variety of new targets as the knowledge of the involved mechanisms progresses. The aim of this work, after revising the limitations of the current treatments, is to perform a thorough review of the mechanisms of action, pharmacokinetics/pharmacodynamics, efficacy, safety, and development stage of the novel ITP therapies under investigation. Hopefully, several of the options included herein may allow us to personalize ITP management according to the needs of each patient in the near future.
Language	English
Publishing date	2022-06-23
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2193542-7
ISSN	1424-8247
ISSN	1424-8247
DOI	10.3390/ph15070779
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: COVID-19 Vaccines and Autoimmune Hematologic Disorders

María Eva Mingot-Castellano / Nora Butta / Mariana Canaro / María del Carmen Gómez del Castillo Solano / Blanca Sánchez-González / Reyes Jiménez-Bárcenas / Cristina Pascual-Izquierdo / Gonzalo Caballero-Navarro / Laura Entrena Ureña / Tomás José González-López / on behalf of the GEPTI

Vaccines, Vol 10, Iss 961, p

2022 Volume 961

Abstract	Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, although the incidence of these AEs is extremely low, their evolution may lead to life-threatening scenarios if treatment is not readily initiated. Hematologic autoimmune AEs have been associated with both mRNA and adenoviral vector-based SARS-CoV-2 vaccines. The main reported entities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans syndrome, and a newly described disorder, so-called vaccine-induced immune thrombotic thrombocytopenia (VITT). The hallmark of VITT is the presence of anti-platelet factor 4 autoantibodies able to trigger platelet activation. Patients with VITT present with thrombocytopenia and may develop thrombosis in unusual locations such as cerebral beds. The management of hematologic autoimmune AEs does not differ significantly from that of these disorders in a non-vaccine context, thus addressing autoantibody production and bleeding/thromboembolic risk. This means that clinicians must be aware of their distinctive signs in order to diagnose them and initiate treatment as soon as possible.
Keywords	COVID-19 ; vaccines ; ITP ; VITT ; TTP ; AIHA and Evans syndrome ; Medicine ; R
Subject code	005
Language	English
Publishing date	2022-06-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.

de Melo Gagliato, Debora / Lei, Xiudong / Giordano, Sharon H / Valero, Vicente / Barcenas, Carlos H / Hortobagyi, Gabriel N / Chavez-MacGregor, Mariana

The oncologist

2020 Volume 25, Issue 9, Page(s) 749–757

Abstract: Background: Delays in the initiation of therapy among patients with early stage breast cancer (BC) can negatively affect outcomes. Patients treated with neoadjuvant systemic chemotherapy (NSC) usually display tumors with high-risk features. Considering ... ...

Abstract	Background: Delays in the initiation of therapy among patients with early stage breast cancer (BC) can negatively affect outcomes. Patients treated with neoadjuvant systemic chemotherapy (NSC) usually display tumors with high-risk features. Considering these high-risk characteristics and the evidence supporting adverse outcomes associated with delays in adjuvant chemotherapy initiation, we sought to determine whether a delay in NSC initiation is associated with overall survival (OS). Methods: We identified patients diagnosed between January 1995 and December 2015 with invasive primary BC (stage I-III) who received NSC at MD Anderson Cancer Center. Patients were categorized according to their time from BC diagnosis to NSC (in days) into three subgroups: 0-30, 31-60, and ≥61 days. Primary endpoint was OS. Descriptive statistics and Cox's proportional hazard models were used. Results: A total of 5,137 patients were included. Median follow-up was 6.5 years. The 5-year OS estimates according to time to NSC were 87%, 85%, and 83% in patients who received NSC within 0-30, 31-60, and ≥61 days after diagnosis, respectively (p = .006). In multivariable analysis, compared with time to NSC of 0-30 days, delayed NSC ≥61 days was associated with an increased risk of death (31-60 days: hazard ratio [HR] = 1.05 [95% confidence interval (CI) 0.92-1.19]; ≥61 days, HR = 1.28 [95% CI 1.06-1.54]). In stratified analyses, the association between delay in NSC initiation and increased risk of death was statistically significant for patients with stage I and II BC (31-60 days: HR = 1.22 [95% CI 1.02-1.47]; ≥61 days, HR = 1.41 [95% CI 1.07-1.86]) and among patients with HER2-positive tumors ( ≥61 days, HR = 1.86 [95% CI 1.21-2.86]). Conclusion: A delay in NSC initiation of more than 61 days after BC diagnosis was associated with an increased risk of death. Early initiation of NSC should be a priority; multidisciplinary teams must focus on coordination of care and patient-centered, timely treatment planning and delivery. Implications for practice: The results of this study showed that a delay in neoadjuvant systemic chemotherapy initiation of more than 61 days after breast cancer diagnosis is associated with an increased risk of death; therefore, efforts must focus on early initiation of therapy, which should be a priority. Multidisciplinary teams must enhance coordination of care and patient-centered, timely treatment planning and delivery.
MeSH term(s)	Breast Neoplasms/drug therapy ; Chemotherapy, Adjuvant ; Female ; Humans ; Neoadjuvant Therapy ; Proportional Hazards Models
Language	English
Publishing date	2020-07-07
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1634/theoncologist.2019-0744
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).

Mingot-Castellano, María Eva / Canaro Hirnyk, Mariana / Sánchez-González, Blanca / Álvarez-Román, María Teresa / Bárez-García, Abelardo / Bernardo-Gutiérrez, Ángel / Bernat-Pablo, Silvia / Bolaños-Calderón, Estefanía / Butta-Coll, Nora / Caballero-Navarro, Gonzalo / Caparrós-Miranda, Isabel Socorro / Entrena-Ureña, Laura / Fernández-Fuertes, Luis Fernando / García-Frade, Luis Javier / Gómez Del Castillo, María Del Carmen / González-López, Tomás José / Grande-García, Carlos / Guinea de Castro, José María / Jarque-Ramos, Isidro /

Jiménez-Bárcenas, Reyes / López-Ansoar, Elsa / Martínez-Carballeira, Daniel / Martínez-Robles, Violeta / Monteagudo-Montesinos, Emilio / Páramo-Fernández, José Antonio / Perera-Álvarez, María Del Mar / Soto-Ortega, Inmaculada / Valcárcel-Ferreiras, David / Pascual-Izquierdo, Cristina

Journal of clinical medicine

2023 Volume 12, Issue 20

Abstract: Primary immune thrombocytopenia (ITP) is a complex autoimmune disease whose hallmark is a deregulation of cellular and humoral immunity leading to increased destruction and reduced production of platelets. The heterogeneity of presentation and clinical ... ...

Abstract	Primary immune thrombocytopenia (ITP) is a complex autoimmune disease whose hallmark is a deregulation of cellular and humoral immunity leading to increased destruction and reduced production of platelets. The heterogeneity of presentation and clinical course hampers personalized approaches for diagnosis and management. In 2021, the Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH) updated a consensus document that had been launched in 2011. The updated guidelines have been the reference for the diagnosis and management of primary ITP in Spain ever since. Nevertheless, the emergence of new tools and strategies makes it advisable to review them again. For this reason, we have updated the main recommendations appropriately. Our aim is to provide a practical tool to facilitate the integral management of all aspects of primary ITP management.
Language	English
Publishing date	2023-10-10
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12206422
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Reliable Assay of Acid Sphingomyelinase Deficiency with the Mutation Q292K by Tandem Mass Spectrometry.

Ghomashchi, Farideh / Barcenas, Mariana / Turecek, Frantisek / Scott, C Ronald / Gelb, Michael H

Clinical chemistry

2015 Volume 61, Issue 5, Page(s) 771–772

MeSH term(s)	Humans ; Mutation ; Niemann-Pick Diseases/enzymology ; Niemann-Pick Diseases/genetics ; Reproducibility of Results ; Sphingomyelin Phosphodiesterase/deficiency ; Sphingomyelin Phosphodiesterase/genetics ; Tandem Mass Spectrometry/methods
Chemical Substances	Sphingomyelin Phosphodiesterase (EC 3.1.4.12)
Language	English
Publishing date	2015-03-13
Publishing country	England
Document type	Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	80102-1
ISSN	1530-8561 ; 0009-9147
ISSN (online)	1530-8561
ISSN	0009-9147
DOI	10.1373/clinchem.2014.236448
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito